Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.55
SHPG's Cash to Debt is ranked higher than
53% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. SHPG: 0.55 )
SHPG' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.55

Equity to Asset 0.57
SHPG's Equity to Asset is ranked higher than
67% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SHPG: 0.57 )
SHPG' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.85
Current: 0.57

0.25
0.85
Interest Coverage 45.50
SHPG's Interest Coverage is ranked higher than
54% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 45.50 )
SHPG' s 10-Year Interest Coverage Range
Min: 2.96   Max: 45.5
Current: 45.5

2.96
45.5
F-Score: 6
Z-Score: 7.12
M-Score: -2.53
WACC vs ROIC
10.55%
32.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.56
SHPG's Operating margin (%) is ranked higher than
96% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. SHPG: 31.56 )
SHPG' s 10-Year Operating margin (%) Range
Min: -56.61   Max: 35.13
Current: 31.56

-56.61
35.13
Net-margin (%) 22.40
SHPG's Net-margin (%) is ranked higher than
94% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. SHPG: 22.40 )
SHPG' s 10-Year Net-margin (%) Range
Min: -59.59   Max: 24.49
Current: 22.4

-59.59
24.49
ROE (%) 23.08
SHPG's ROE (%) is ranked higher than
96% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. SHPG: 23.08 )
SHPG' s 10-Year ROE (%) Range
Min: -90.18   Max: 30.69
Current: 23.08

-90.18
30.69
ROA (%) 12.72
SHPG's ROA (%) is ranked higher than
95% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. SHPG: 12.72 )
SHPG' s 10-Year ROA (%) Range
Min: -37.5   Max: 14.7
Current: 12.72

-37.5
14.7
ROC (Joel Greenblatt) (%) 139.80
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. SHPG: 139.80 )
SHPG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -412.29   Max: 315.7
Current: 139.8

-412.29
315.7
Revenue Growth (3Y)(%) 10.70
SHPG's Revenue Growth (3Y)(%) is ranked higher than
85% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. SHPG: 10.70 )
SHPG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.7   Max: 26.8
Current: 10.7

-0.7
26.8
EBITDA Growth (3Y)(%) 22.80
SHPG's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SHPG: 22.80 )
SHPG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -1.4   Max: 32.6
Current: 22.8

-1.4
32.6
EPS Growth (3Y)(%) 31.80
SHPG's EPS Growth (3Y)(%) is ranked higher than
93% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. SHPG: 31.80 )
SHPG' s 10-Year EPS Growth (3Y)(%) Range
Min: -7   Max: 62.8
Current: 31.8

-7
62.8
» SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SHPG Guru Trades in Q1 2014

Ken Fisher 2,447 sh (+4.57%)
Murray Stahl 6,000 sh (unchged)
John Paulson 2,529,854 sh (unchged)
Jim Simons 561,700 sh (-9.29%)
Pioneer Investments 61,509 sh (-28.35%)
Steven Cohen 66,000 sh (-42.96%)
Andreas Halvorsen 399,840 sh (-67.31%)
» More
Q2 2014

SHPG Guru Trades in Q2 2014

Louis Moore Bacon 5,000 sh (New)
Eric Mindich 251,000 sh (New)
Ken Fisher 4,677 sh (+91.13%)
John Paulson 3,366,539 sh (+33.07%)
Jim Simons 675,575 sh (+20.27%)
Murray Stahl 6,000 sh (unchged)
Andreas Halvorsen Sold Out
Pioneer Investments 36,744 sh (-40.26%)
» More
Q3 2014

SHPG Guru Trades in Q3 2014

David Tepper 185,944 sh (New)
Jean-Marie Eveillard 15,000 sh (New)
Paul Singer 107,800 sh (New)
Richard Perry 695,800 sh (New)
Mario Gabelli 37,850 sh (New)
Jeremy Grantham 1,845,359 sh (New)
Daniel Loeb 750,000 sh (New)
Louis Moore Bacon 45,300 sh (+806%)
John Paulson 9,046,000 sh (+168.7%)
Murray Stahl 6,000 sh (unchged)
Pioneer Investments Sold Out
Ken Fisher 2,827 sh (-39.56%)
Jim Simons 320,312 sh (-52.59%)
Eric Mindich 76,781 sh (-69.41%)
» More
Q4 2014

SHPG Guru Trades in Q4 2014

Ken Fisher 14,594 sh (+416.24%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-12-31 Add 416.24%0.01%$170.49 - $262.71 $ 222.175%14594
Richard Perry 2014-09-30 New Buy6.5%$231.98 - $262.64 $ 222.17-10%695800
John Paulson 2014-09-30 Add 168.7%6.09%$231.98 - $262.64 $ 222.17-10%9046000
Daniel Loeb 2014-09-30 New Buy2.2%$231.98 - $262.64 $ 222.17-10%750000
David Tepper 2014-09-30 New Buy0.71%$231.98 - $262.64 $ 222.17-10%185944
Mario Gabelli 2014-09-30 New Buy0.05%$231.98 - $262.64 $ 222.17-10%37850
Jean-Marie Eveillard 2014-09-30 New Buy0.01%$231.98 - $262.64 $ 222.17-10%15000
Ken Fisher 2014-09-30 Reduce -39.56%$231.98 - $262.64 $ 222.17-10%2827
John Paulson 2014-06-30 Add 33.07%0.84%$142.83 - $234.98 $ 222.1728%3366539
Andreas Halvorsen 2014-06-30 Sold Out 0.25%$142.83 - $234.98 $ 222.1728%0
Ken Fisher 2014-06-30 Add 91.13%$142.83 - $234.98 $ 222.1728%4677
Andreas Halvorsen 2014-03-31 Reduce -67.31%0.55%$139.18 - $171.77 $ 222.1744%399840
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Shire PLC

Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion
Following a number of pharma mergers last year, which included the likes of Actavis and Forest Laboratories, Shire (SHPG) announced on Jan. 11 that it is acquiring NPS Pharmaceuticals (NPSP) for $5.2 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 37.30
SHPG's P/E(ttm) is ranked higher than
94% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 37.30 )
SHPG' s 10-Year P/E(ttm) Range
Min: 14.57   Max: 74.35
Current: 37.3

14.57
74.35
Forward P/E 11.29
SHPG's Forward P/E is ranked higher than
98% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 11.29 )
N/A
PE(NRI) 25.90
SHPG's PE(NRI) is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 25.90 )
SHPG' s 10-Year PE(NRI) Range
Min: 12.35   Max: 106.92
Current: 25.9

12.35
106.92
P/B 7.30
SHPG's P/B is ranked higher than
71% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. SHPG: 7.30 )
SHPG' s 10-Year P/B Range
Min: 1.93   Max: 14.23
Current: 7.3

1.93
14.23
P/S 8.30
SHPG's P/S is ranked higher than
84% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. SHPG: 8.30 )
SHPG' s 10-Year P/S Range
Min: 2.25   Max: 9.26
Current: 8.3

2.25
9.26
PFCF 24.70
SHPG's PFCF is ranked higher than
97% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 24.70 )
SHPG' s 10-Year PFCF Range
Min: 9.21   Max: 44
Current: 24.7

9.21
44
POCF 21.03
SHPG's POCF is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 21.03 )
SHPG' s 10-Year POCF Range
Min: 7.59   Max: 26.82
Current: 21.03

7.59
26.82
EV-to-EBIT 26.49
SHPG's EV-to-EBIT is ranked higher than
94% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 26.49 )
SHPG' s 10-Year EV-to-EBIT Range
Min: -14.6   Max: 58.7
Current: 26.49

-14.6
58.7
PEG 1.47
SHPG's PEG is ranked higher than
99% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 1.47 )
SHPG' s 10-Year PEG Range
Min: 0.93   Max: 1.83
Current: 1.47

0.93
1.83
Shiller P/E 54.90
SHPG's Shiller P/E is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 54.90 )
SHPG' s 10-Year Shiller P/E Range
Min: 30.76   Max: 143.7
Current: 54.9

30.76
143.7
Current Ratio 1.43
SHPG's Current Ratio is ranked higher than
56% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. SHPG: 1.43 )
SHPG' s 10-Year Current Ratio Range
Min: 0.67   Max: 7.43
Current: 1.43

0.67
7.43
Quick Ratio 1.16
SHPG's Quick Ratio is ranked higher than
56% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. SHPG: 1.16 )
SHPG' s 10-Year Quick Ratio Range
Min: 0.53   Max: 7.07
Current: 1.16

0.53
7.07
Days Inventory 211.89
SHPG's Days Inventory is ranked higher than
82% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 211.89 )
SHPG' s 10-Year Days Inventory Range
Min: 113.08   Max: 270.35
Current: 211.89

113.08
270.35
Days Sales Outstanding 69.31
SHPG's Days Sales Outstanding is ranked higher than
80% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. SHPG: 69.31 )
SHPG' s 10-Year Days Sales Outstanding Range
Min: 47.71   Max: 101.67
Current: 69.31

47.71
101.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.30
SHPG's Dividend Yield is ranked lower than
89% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. SHPG: 0.30 )
SHPG' s 10-Year Dividend Yield Range
Min: 0.16   Max: 0.7
Current: 0.3

0.16
0.7
Dividend Payout 0.07
SHPG's Dividend Payout is ranked higher than
100% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 0.07 )
SHPG' s 10-Year Dividend Payout Range
Min: 0.05   Max: 1.23
Current: 0.07

0.05
1.23
Dividend growth (3y) 15.50
SHPG's Dividend growth (3y) is ranked higher than
90% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. SHPG: 15.50 )
SHPG' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 57.9
Current: 15.5

0
57.9
Yield on cost (5-Year) 0.56
SHPG's Yield on cost (5-Year) is ranked lower than
77% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. SHPG: 0.56 )
SHPG' s 10-Year Yield on cost (5-Year) Range
Min: 0.3   Max: 1.31
Current: 0.56

0.3
1.31

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.20
SHPG's Price/DCF (Projected) is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 2.20 )
SHPG' s 10-Year Price/DCF (Projected) Range
Min: 1.13   Max: 2.65
Current: 2.2

1.13
2.65
Price/Median PS Value 1.80
SHPG's Price/Median PS Value is ranked higher than
75% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. SHPG: 1.80 )
SHPG' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 3
Current: 1.8

0.57
3
Price/Peter Lynch Fair Value 1.30
SHPG's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPG: 1.30 )
SHPG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.72   Max: 2.92
Current: 1.3

0.72
2.92
Earnings Yield (Greenblatt) 3.80
SHPG's Earnings Yield (Greenblatt) is ranked higher than
94% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. SHPG: 3.80 )
SHPG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.7   Max: 16.9
Current: 3.8

1.7
16.9
Forward Rate of Return (Yacktman) 19.23
SHPG's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 14.57 vs. SHPG: 19.23 )
SHPG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.5   Max: 26
Current: 19.23

1.5
26

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SHP.UK, SHPGF.USA, S7E.Germany, SP2.Germany,
Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address significant unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 
Invesco European Growth Fund Comments on Shire PLC Dec 30 2014 
Invesco European Growth Fund Q4 2014 Management’s Discussion Dec 30 2014 
Activist Investor Dan Loeb Stays Active in Third Quarter Dec 08 2014 
David Tepper Buys 4 New Stocks in Q3 Nov 18 2014 
Invesco European Growth Fund Q3 2014 Commentary Oct 29 2014 
Weekly 52-Week Highs Highlight: KSS, SHPG, LB, RSG Sep 28 2014 
Invesco European Growth Fund Comments on Shire PLC Jul 29 2014 
Invesco European Growth Fund Second Quarter 2014 Commentary Jul 29 2014 
Weekly 52-Week Highs Highlight: SHPG, ILMN, UA, WDAY Feb 23 2014 


More From Other Websites
Bill Ackman on Receiving End of Hedge Fund Selling Jan 28 2015
ETFs To Tap Into Greater M&A Activity Jan 28 2015
NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst Blog Jan 27 2015
U.S. Supreme Court Grants Shire Petition Jan 27 2015
How Will M&A ETFs Perform In 2015? Many Deals Lined Up Jan 26 2015
Shire's Elvanse Gets Positive Response for ADHD in Adults - Analyst Blog Jan 26 2015
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jan 26 2015
Why I Would Buy International Consolidated Airlines Grp And Shire PLC But Sell Enquest Plc Jan 26 2015
Shire Comments on FDA Approval of Natpara�® Jan 26 2015
Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the... Jan 26 2015
Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid... Jan 23 2015
Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog Jan 23 2015
The Zacks Analyst Blog Highlights: Alcatel-Lucent, Intercontinental Hotels Group and Shire - Press... Jan 22 2015
Shire Added to Global 100 Sustainability Index Jan 22 2015
Positive Response From European Decentralised Procedure for Elvanse Adult® ▼ (lisdexamfetamine... Jan 22 2015
Positive Response from European Decentralised Procedure for Elvanse Adult®▼ (lisdexamfetamine... Jan 22 2015
Valeant's Bausch + Lomb Imaging System Cleared by FDA - Analyst Blog Jan 21 2015
Shire Added to Global 100 Sustainability Index Jan 21 2015
CytRx Relieved as FDA Lifts Partial Hold on Oncology Drug - Analyst Blog Jan 21 2015
Beating the Greece Scare: 3 Stock Picks - Analyst Blog Jan 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK